On Wednesday, RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm ...
RBC Capital Markets adjusted its price target for Amgen (NASDAQ:AMGN) shares, reducing it slightly from $324 to $320, while retaining an Outperform rating on the biotechnology firm's stock. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback